1. PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
   Anne Perdrix et al, 2017, Cancers CrossRef
2. Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models
   Giuseppina Barutello et al, 2022, Biomedicines CrossRef
3. Assessment and process optimization of high throughput biofabrication of immunocompetent breast cancer model for drug screening applications
   Priyanshu Shukla et al, 2024, Biofabrication CrossRef
4. RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity
   Johannes Ristau et al, 2019, Cell Death & Disease CrossRef
5. Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy
   Oleg Timofeev et al, 2021, Cancers CrossRef
6. Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile
   Kate Brown et al, 2023, Frontiers in Oncology CrossRef
7. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53
   Satish K. Ramraj et al, 2020, International Journal of Cancer CrossRef
8. Discovery of compounds that reactivate p53 mutants in vitro and in vivo
   Geetha Durairaj et al, 2022, Cell Chemical Biology CrossRef
9. Therapeutic Inducers of Apoptosis in Ovarian Cancer
   Mudra Binju et al, 2019, Cancers CrossRef
10. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
    María Ovejero-Sánchez et al, 2023, Cancers CrossRef
11. Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies
    Jolanda Magri et al, 2021, Cells CrossRef
12. APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation
    Teruyuki Kobayashi et al, 2021, British Journal of Cancer CrossRef
13. The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells
    Ibtehal Mohammed et al, 2023, Investigational New Drugs CrossRef
14. DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies
    Mohammad Mirza-Aghazadeh-Attari et al, 2019, DNA Repair CrossRef
15. Mutant p53 as a target for cancer treatment
    Michael J. Duffy et al, 2017, European Journal of Cancer CrossRef
16. PTC596-Induced BMI-1 Inhibition Fights Neuroblastoma Multidrug Resistance by Inducing Ferroptosis
    Giulia Elda Valenti et al, 2023, Antioxidants CrossRef
17. Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
    Anna N. Cvrljevic et al, 2022, Molecular Cancer Therapeutics CrossRef
18. Inhibiting system xC− and glutathione biosynthesis – a potential Achilles' heel in mutant-p53 cancers
    Nicholas J. Clemons et al, 2017, Molecular & Cellular Oncology CrossRef
19. The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer
    Bryce Wallis et al, 2023, Biomolecules CrossRef
20. p53 and metabolism: from mechanism to therapeutics
    Fernando M. Simabuco et al, 2018, Oncotarget CrossRef
21. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
    Ana Herrero et al, 2016, International Journal of Molecular Sciences CrossRef
22. PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells
    Zuzana Jaskova et al, 2020, Leukemia Research CrossRef
23. PRIMA-1MET Does Not Restore Vitamin D Sensitivity to MDA-MB-231 and MDA-MB-468 Triple-Negative Breast Cancer Cells
    Shadi N. Kotob et al, 2023, ACS Omega CrossRef